Research Groups

Mechanisms of Carcinogenesis - Molecular Mechanisms and Biomarkers Group

Key Recent Publications

1. Jelakovic, B., Castells, X., Tomic, K., Ardin, M., Karanovic, S., and Zavadil, J. (2014) Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer :Epub ahead of print doi: 10.1002/ijc.29338. PubMed PMID: 25403517

2. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanche H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM (2014) Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 5:5135

3. Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J (2014) Modelling mutational landscapes of human cancers in vitro. Sci Rep 4:4482

4. Hollstein M, Moriya M, Grollman AP, Olivier M (2013) Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res 753(1):41-9

5. Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP (2012) Upper urinary tract urothelial cancers: where it is A:T. Nat Rev Cancer 12(8):503-4

6. Editors: Hainaut P, Olivier M, Wiman K (2013) Prognostic and predictive value of TP53 mutations in human cancer. p53 in the clinics. Springer, New York [Book] X:355 pages

7. Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K, Quinaux E, Buyse M, Dolci MS, De Azambuja E, Hainaut P, Dell\\\'Orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Di Leo A, and Olivier M (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14(3):R70

8. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK, Hainaut P: the EUELC Consortium (2012) Prognostic value of TP53, KRAS and EGFR mutations in Non-Small Cell Lung Cancer: EUELC cohort. Eur Respir J 40(1):177-84

9. Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van der Sande M, Whittle H, Friesen MD, Groopman JD, Hainaut P (2011) Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection. Environ Health Perspect 119(11):1635-40

10. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P (2012) Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 118(5):1387-96

11. Olivier M, Taniere P (2011) Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Curr Opin Oncol 23(1):88-92

12. Anaganti S, Fernandez-Cuesta L, Langerød A, Hainaut P, Olivier M (2011) p53-dependent repression of Focal Adhesion Kinase in response to estradiol in breast cancer cell-lines. Cancer Letters 300(2):215-24

13. Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M (2011) p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer 128:1813–21